Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Lilly (NYSE:LLY) has also applied to have Omvoh approved by the FDA for the treatment of moderately to severely active Crohn's disease. A decision expected in the first half of 2025.

Omvoh is currently approved in more than 44 countries, including the United States and Europe, to treat adults with moderate-to-severely active ulcerative colitis (“UC”). LLY Stock’s Performance ...

As recently as March, the FDA approved the IL-23 inhibitor guselkumab (Tremfya, Johnson & Johnson/Janssen) for patients with ...

Lilly said the new drug – which will be sold under the Omvoh brand – will be launched in the coming weeks. It has already been approved under the same trade name in Europe and Japan ...